AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Qscreen Ai Inc.
Video analysis: PMEDF
All videosNo video analysis for this stock yet. Request one from our team.
News: PMEDF
QScreen AI Announces Closing of Final Tranche of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - September 9, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, is pleased to announce the closing of the final tranche of its previously announced non-brokered private placement. The Company is pleased to announce that it has completed the final tranche of its previously announced non-brokered private placement through the issuance of 6,153,256 units (the "Units") at a price of $0.05 per Unit for gross proceeds of approximately $307,662.80.
QScreen AI Deepens US Institutional Pipeline as Screening Platform Adds Escalation-Based Review Capability
Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - QScreen AI Inc. (CSE: QAI) (OTC: PMEDF) (FSE: 3QP) ("QScreen" or the "Company") today announced completion of the tiered screening architecture at the core of its commercialization strategy. The architecture is fully implemented in the Company's browser-based platform and is now being demonstrated to prospective institutional partners through the Company's US channel process, where a first signed evaluation agreement remains the stated near-term milestone.
QScreen AI Secures Second US Patent, Extending Single-Camera Impairment Detection on Standard Hardware
Toronto, Ontario--(Newsfile Corp. - July 14, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or the "Company") now holds two granted US patents covering its core impairment-detection method, after the United States Patent and Trademark Office granted the Company US Patent No. 12,640,164, "Systems and Methods for Detecting Impairment of an Individual," on May 26, 2026.
QScreen AI Announces Adoption of Semi-Annual Reporting
Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions in Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). Introduced by the Canadian Securities Administrators (CSA), the pilot program under CBO 51-933 allows eligible venture issuers to voluntarily transition from quarterly to semi-annual financial reporting.
QScreen AI Announces Close of First Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, is pleased to announce the closing of the first tranche of its previously announced non-brokered private placement. The Company is pleased to announce that it has completed the first tranche of its previously announced non-brokered private placement through the issuance of 4,876,400 units (the "Units") at a price of $0.05 per Unit for gross proceeds of approximately $243,820.
